MASH

Latest News

February 6th 2025

As a growing number of young adults with primary liver cancer (PLC) related to metabolic dysfunction–associated steatohepatitis (MASH) age, developing coherent strategies to combat the metabolic disease epidemic is critical.

The investigators believe their decades-spanning analysis underscores the need to address access barriers to anti-obesity therapeutics | image credit: TAW4 - stock.adobe.com

January 28th 2025

"Alarming Rise" of Global MASH-Related Primary Liver Cancer Incidence Since 2000

By Kyle Munz

The management of MASH for those on a GLP-1RA could benefit from the edition of efruxifermin | image credit: Crystal Light - stock.adobe.com

January 27th 2025

Amplifying Impact: Efruxifermin Plus GLP-1RA Elevates MASH Outcomes

By Kyle Munz

MASH is the inflammatory, progressed form of MASLD | image credit: Rasi - stock.adobe.com

January 20th 2025

A Potential Early Biomarker for MASLD: Oxidized Apolipoproteins

By Kyle Munz

Man holding liver illustration - SewcreamStudio - stock.adobe.com

June 12th 2024

Study Highlights Increasing Global Health Burden of Liver Cancer

By Rose McNulty

Blue FDA approved stamp | Imaged credit: Olivier Le Moal - stock.adobe.com

FDA Approves Resmetirom, First Treatment for NASH With Liver Fibrosis

ByLaura Joszt, MA

March 14th 2024

The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.

ICER to Assess Clinical Effectiveness, Value of 2 NASH Treatments

ByLaura Joszt, MA

October 11th 2022

There are no FDA-approved therapies for nonalcoholic steatohepatitis (NASH), but there are many being developed. Resmetirom and obeticholic acid are both being reviewed by the FDA with decisions expected in 2023.